VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Relapse after HSCT 2021 | The efficacy of ATO and ATRA for APL

Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the APL0406 clinical trial (NCT00482833) that led to the approval of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) without chemotherapy for the treatment of acute promyelocytic leukemia (APL). This trial demonstrated that patients treated only with ATO+ATRA experienced long-term survival rates between 95-100%. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter